| Year |
Citation |
Score |
| 2023 |
Verhoeven J, Jacobs KA, Rizzollo F, Lodi F, Hua Y, Poźniak J, Narayanan Srinivasan A, Houbaert D, Shankar G, More S, Schaaf MB, Dubroja Lakic N, Ganne M, Lamote J, Van Weyenbergh J, ... ... Bergers G, et al. Tumor endothelial cell autophagy is a key vascular-immune checkpoint in melanoma. Embo Molecular Medicine. 15: e18028. PMID 38009521 DOI: 10.15252/emmm.202318028 |
0.396 |
|
| 2023 |
Vella G, Hua Y, Bergers G. High endothelial venules in cancer: Regulation, function, and therapeutic implication. Cancer Cell. 41: 527-545. PMID 36827979 DOI: 10.1016/j.ccell.2023.02.002 |
0.396 |
|
| 2022 |
Hua Y, Vella G, Rambow F, Allen E, Antoranz Martinez A, Duhamel M, Takeda A, Jalkanen S, Junius S, Smeets A, Nittner D, Dimmeler S, Hehlgans T, Liston A, Bosisio FM, ... ... Bergers G, et al. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1 T lymphocyte niches through a feed-forward loop. Cancer Cell. PMID 36423635 DOI: 10.1016/j.ccell.2022.11.002 |
0.36 |
|
| 2021 |
Vella G, Guelfi S, Bergers G. High Endothelial Venules: A Vascular Perspective on Tertiary Lymphoid Structures in Cancer. Frontiers in Immunology. 12: 736670. PMID 34484246 DOI: 10.3389/fimmu.2021.736670 |
0.432 |
|
| 2019 |
Hua Y, Bergers G. Tumors vs. Chronic Wounds: An Immune Cell's Perspective. Frontiers in Immunology. 10: 2178. PMID 31572387 DOI: 10.3389/Fimmu.2019.02178 |
0.487 |
|
| 2019 |
Säälik P, Lingasamy P, Toome K, Mastandrea I, Rousso-Noori L, Tobi A, Simón-Gracia L, Hunt H, Paiste P, Kotamraju VR, Bergers G, Asser T, Rätsep T, Ruoslahti E, Bjerkvig R, et al. Peptide-guided nanoparticles for glioblastoma targeting. Journal of Controlled Release : Official Journal of the Controlled Release Society. 308: 109-118. PMID 31255690 DOI: 10.1016/J.Jconrel.2019.06.018 |
0.445 |
|
| 2019 |
Mazzone M, Bergers G. Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis. Annual Review of Physiology. 81: 535-560. PMID 30742781 DOI: 10.1146/Annurev-Physiol-020518-114721 |
0.468 |
|
| 2018 |
Vella G, Bergers G. Where Have All the T Cells Gone Immunity. 49: 592-594. PMID 30332627 DOI: 10.1016/J.Immuni.2018.10.006 |
0.379 |
|
| 2018 |
Barnes JM, Kaushik S, Bainer RO, Sa JK, Woods EC, Kai F, Przybyla L, Lee M, Lee HW, Tung JC, Maller O, Barrett AS, Lu KV, Lakins JN, Hansen KC, ... ... Bergers G, et al. A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma. Nature Cell Biology. PMID 30202050 DOI: 10.1038/S41556-018-0183-3 |
0.364 |
|
| 2018 |
Missiaen R, Mazzone M, Bergers G. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Seminars in Cancer Biology. PMID 29935312 DOI: 10.1016/J.Semcancer.2018.06.002 |
0.535 |
|
| 2018 |
Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, et al. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. PMID 29766399 DOI: 10.1007/S10456-018-9613-X |
0.358 |
|
| 2018 |
He B, Jabouille A, Steri V, Johansson-Percival A, Michael IP, Kotamraju VR, Junckerstorff R, Nowak AK, Hamzah J, Lee G, Bergers G, Ganss R. Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoral high endothelial venules. The Journal of Pathology. PMID 29603739 DOI: 10.1002/Path.5080 |
0.422 |
|
| 2017 |
Allen E, Missiaen R, Bergers G. Therapeutic induction of high endothelial venules (HEVs) to enhance T-cell infiltration in tumors. Oncotarget. 8: 99207-99208. PMID 29245888 DOI: 10.18632/Oncotarget.22276 |
0.508 |
|
| 2017 |
Jahangiri A, Nguyen A, Chandra A, Sidorov MK, Yagnik G, Rick J, Han SW, Chen W, Flanigan PM, Schneidman-Duhovny D, Mascharak S, De Lay M, Imber B, Park CC, Matsumoto K, ... ... Bergers G, et al. Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 28973887 DOI: 10.1073/Pnas.1701821114 |
0.347 |
|
| 2017 |
Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, Bergers G. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Science Translational Medicine. 9. PMID 28404866 DOI: 10.1126/Scitranslmed.Aak9679 |
0.467 |
|
| 2017 |
Allen E, Missiaen R, Bergers G. Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations. Cold Spring Harbor Symposia On Quantitative Biology. PMID 28396525 DOI: 10.1101/Sqb.2016.81.030940 |
0.551 |
|
| 2017 |
Barnes JM, Woods EC, Bainer RO, Miroshnikova YA, Lu K, Bergers G, Bertozzi C, Weaver VM. Abstract PR05: Glycoprotein-mediated tissue mechanics regulate glioblastoma aggression Cancer Research. 77. DOI: 10.1158/1538-7445.Epso16-Pr05 |
0.492 |
|
| 2016 |
Säälik P, Hunt H, Tobi A, Willmore AA, Toome K, Sharma S, Kotamraju R, Bergers G, Bjerkvig R, Ruoslahti E, Teesalu T. Abstract 1343: P32-targeting TT1 peptide delivers nanoparticles to intracranial glioblastomas Cancer Research. 76: 1343-1343. DOI: 10.1158/1538-7445.Am2016-1343 |
0.388 |
|
| 2016 |
Steri V, Oronsky B, Scicinski J, Bergers G. Abstract 1245: RRx-001 is effective in temozolomide-sensitive and resistant GBM Cancer Research. 76: 1245-1245. DOI: 10.1158/1538-7445.Am2016-1245 |
0.493 |
|
| 2015 |
Hambardzumyan D, Bergers G. Glioblastoma: Defining Tumor Niches. Trends in Cancer. 1: 252-265. PMID 27088132 DOI: 10.1016/J.Trecan.2015.10.009 |
0.547 |
|
| 2015 |
Rivera LB, Bergers G. Tumor angiogenesis, from foe to friend Science. 349: 694-695. PMID 26273044 DOI: 10.1126/Science.Aad0862 |
0.526 |
|
| 2015 |
Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Reports. 11: 577-91. PMID 25892230 DOI: 10.1016/J.Celrep.2015.03.055 |
0.547 |
|
| 2015 |
Rivera LB, Bergers G. Intertwined regulation of angiogenesis and immunity by myeloid cells Trends in Immunology. 36: 240-249. PMID 25770923 DOI: 10.1016/J.It.2015.02.005 |
0.538 |
|
| 2015 |
Bergers G. Abstract IA24: Understanding and tackling differing vascular niches in glioma Brain. 75. DOI: 10.1158/1538-7445.Brain15-Ia24 |
0.553 |
|
| 2015 |
Lu K, Hambardzumyan D, Bergers G. CBIO-05UNDERSTANDING AND TACKLING PARACRINE SIGNALING CUES BETWEEN GLIOMA AND IMMUNE CELLS TO THWART GLIOMA INVASIVENESS AND ANGIOGENESIS Neuro-Oncology. 17: v55.5-v56. DOI: 10.1093/Neuonc/Nov209.05 |
0.554 |
|
| 2014 |
Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. Nmr in Biomedicine. 27: 1361-70. PMID 25199993 DOI: 10.1002/Nbm.3198 |
0.305 |
|
| 2014 |
Rivera LB, Bergers G. Targeting vascular sprouts Science. 344: 1449-1450. PMID 24970064 DOI: 10.1126/Science.1257071 |
0.488 |
|
| 2014 |
Hyvönen M, Enbäck J, Huhtala T, Lammi J, Sihto H, Weisell J, Joensuu H, Rosenthal-Aizman K, El-Andaloussi S, Langel U, Närvänen A, Bergers G, Laakkonen PM. Novel Target for Peptide-Based Imaging and Treatment of Brain Tumors Molecular Cancer Therapeutics. 13: 996-1007. PMID 24493698 DOI: 10.1158/1535-7163.Mct-13-0684 |
0.473 |
|
| 2014 |
Rivera L, Pandika M, Bergers G. Escape Mechanisms from Antiangiogenic Therapy: An Immune Cell’s Perspective Advances in Experimental Medicine and Biology. 772: 83-99. PMID 24272355 DOI: 10.1007/978-1-4614-5915-6_4 |
0.555 |
|
| 2014 |
Persson AI, Ilkhanizadeh S, Miroshnikova YA, Frantz A, Lakins JN, James CD, McKnight TR, Berger MS, Bergers G, Weiss WA, Weaver VM. HIGH INTERSTITIAL FLUID PRESSURE REGULATES TUMOR GROWTH AND DRUG UPTAKE IN HUMAN GLIOBLASTOMA Neuro-Oncology. 16: iii32-iii32. DOI: 10.1093/Neuonc/Nou208.37 |
0.473 |
|
| 2014 |
Bergers G, Lu K, Rivera L. Understanding And Tackling The Tumor-Immune Cell Dialogue During Progression And Therapeutic Resistance. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou206.59 |
0.528 |
|
| 2013 |
Rivera LB, Bergers G. Location, Location, Location: Macrophage Positioning within Tumors Determines Pro- or Antitumor Activity Cancer Cell. 24: 687-689. PMID 24332035 DOI: 10.1016/J.Ccr.2013.11.014 |
0.472 |
|
| 2013 |
Lu KV, Bergers G. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. Cns Oncology. 2: 49-65. PMID 23750318 DOI: 10.2217/Cns.12.36 |
0.47 |
|
| 2013 |
Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, ... Bergers G, et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1773-83. PMID 23307858 DOI: 10.1158/1078-0432.Ccr-12-1281 |
0.387 |
|
| 2012 |
Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 22: 21-35. PMID 22789536 DOI: 10.1016/J.Ccr.2012.05.037 |
0.534 |
|
| 2011 |
Sugiarto S, Persson AI, Munoz EG, Waldhuber M, Lamagna C, Andor N, Hanecker P, Ayers-Ringler J, Phillips J, Siu J, Lim DA, Vandenberg S, Stallcup W, Berger MS, Bergers G, et al. Asymmetry-defective oligodendrocyte progenitors are glioma precursors. Cancer Cell. 20: 328-40. PMID 21907924 DOI: 10.1016/J.Ccr.2011.08.011 |
0.351 |
|
| 2011 |
Dvorak HF, Weaver VM, Tlsty TD, Bergers G. Tumor microenvironment and progression. Journal of Surgical Oncology. 103: 468-74. PMID 21480238 DOI: 10.1002/Jso.21709 |
0.538 |
|
| 2010 |
Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, Auvergne R, Goldenberg DD, Vandenberg SR, Nguyen KN, Yakovenko S, Ayers-Ringler J, Nishiyama A, Stallcup WB, Berger MS, Bergers G, et al. Non-stem cell origin for oligodendroglioma. Cancer Cell. 18: 669-82. PMID 21156288 DOI: 10.1016/J.Ccr.2010.10.033 |
0.485 |
|
| 2009 |
Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, ... ... Bergers G, et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Research. 69: 6889-98. PMID 19690143 DOI: 10.1158/0008-5472.Can-09-0347 |
0.452 |
|
| 2009 |
Pà ez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 15: 220-31. PMID 19249680 DOI: 10.1016/J.Ccr.2009.01.027 |
0.505 |
|
| 2008 |
Lu K, Lamagna C, Bergers G. Chapter 3. Bone marrow-derived vascular progenitors and proangiogenic monocytes in tumors. Methods in Enzymology. 445: 53-82. PMID 19022055 DOI: 10.1016/S0076-6879(08)03003-6 |
0.523 |
|
| 2008 |
Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Reviews. Cancer. 8: 592-603. PMID 18650835 DOI: 10.1038/Nrc2442 |
0.405 |
|
| 2008 |
Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. Bmc Medicine. 6: 14. PMID 18577219 DOI: 10.1186/1741-7015-6-14 |
0.409 |
|
| 2008 |
Du R, Petritsch C, Lu K, Liu P, Haller A, Ganss R, Song H, Vandenberg S, Bergers G. Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro-Oncology. 10: 254-64. PMID 18359864 DOI: 10.1215/15228517-2008-001 |
0.504 |
|
| 2008 |
Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegué E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 13: 206-20. PMID 18328425 DOI: 10.1016/J.Ccr.2008.01.034 |
0.527 |
|
| 2008 |
Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. Plos Medicine. 5: e19. PMID 18232728 DOI: 10.1371/Journal.Pmed.0050019 |
0.503 |
|
| 2007 |
Chesler L, Goldenberg DD, Seales IT, Satchi-Fainaro R, Grimmer M, Collins R, Struett C, Nguyen KN, Kim G, Tihan T, Bao Y, Brekken RA, Bergers G, Folkman J, Weiss WA. Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Research. 67: 9435-42. PMID 17909053 DOI: 10.1158/0008-5472.Can-07-1316 |
0.547 |
|
| 2007 |
Blouw B, Haase VH, Song H, Bergers G, Johnson RS. Loss of vascular endothelial growth factor expression reduces vascularization, but not growth, of tumors lacking the Von Hippel-Lindau tumor suppressor gene. Oncogene. 26: 4531-40. PMID 17297464 DOI: 10.1038/Sj.Onc.1210249 |
0.527 |
|
| 2006 |
Kawaguchi T, Yamashita Y, Kanamori M, Endersby R, Bankiewicz KS, Baker SJ, Bergers G, Pieper RO. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Research. 66: 11331-40. PMID 17145879 DOI: 10.1158/0008-5472.Can-06-1540 |
0.516 |
|
| 2006 |
Lamagna C, Bergers G. The bone marrow constitutes a reservoir of pericyte progenitors. Journal of Leukocyte Biology. 80: 677-681. PMID 16888086 DOI: 10.1189/Jlb.0506309 |
0.382 |
|
| 2006 |
Holash J, Thurston G, Rudge JS, Yancopoulos GD, Adjei AA, Bergers G, Pytowski B, Pegram M, Gordon MS. Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. Cancer Metastasis Reviews. 25: 243-52. PMID 16770536 DOI: 10.1007/S10555-006-8504-6 |
0.335 |
|
| 2006 |
Du R, Petritsch C, Song H, Werb Z, Bergers G. ID: 373 MMP-9-dependent regulation of angiogenesis and invasion in GBM Journal of Thrombosis and Haemostasis. 4: 46-46. DOI: 10.1111/J.1538-7836.2006.00373.X |
0.311 |
|
| 2005 |
Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 8: 299-309. PMID 16226705 DOI: 10.1016/J.Ccr.2005.09.005 |
0.532 |
|
| 2005 |
Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro-Oncology. 7: 452-64. PMID 16212810 DOI: 10.1215/S1152851705000232 |
0.435 |
|
| 2005 |
Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival Nature Cell Biology. 7: 870-879. PMID 16113679 DOI: 10.1038/Ncb1288 |
0.414 |
|
| 2005 |
Berger M, Bergers G, Arnold B, Hämmerling GJ, Ganss R. Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood. 105: 1094-1101. PMID 15459006 DOI: 10.1182/Blood-2004-06-2315 |
0.533 |
|
| 2004 |
Kanamori M, Vanden Berg SR, Bergers G, Berger MS, Pieper RO. Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme. Cancer Research. 64: 2751-8. PMID 15087390 DOI: 10.1158/0008-5472.Can-03-3354 |
0.432 |
|
| 2003 |
Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 4: 393-403. PMID 14667506 DOI: 10.1016/S1535-6108(03)00271-X |
0.474 |
|
| 2003 |
Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, Johnson RS, Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell. 4: 133-46. PMID 12957288 DOI: 10.1016/S1535-6108(03)00194-6 |
0.496 |
|
| 2003 |
Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nature Reviews. Cancer. 3: 401-10. PMID 12778130 DOI: 10.1038/Nrc1093 |
0.337 |
|
| 2003 |
Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. The Journal of Clinical Investigation. 111: 1287-95. PMID 12727920 DOI: 10.1172/Jci17929 |
0.507 |
|
| 2001 |
Toft DJ, Rosenberg SB, Bergers G, Volpert O, Linzer DI. Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression. Proceedings of the National Academy of Sciences of the United States of America. 98: 13055-9. PMID 11606769 DOI: 10.1073/Pnas.231364798 |
0.495 |
|
| 2001 |
Bergers G, Hanahan D. Cell factories for fighting cancer. Nature Biotechnology. 19: 20-1. PMID 11135544 DOI: 10.1038/83457 |
0.305 |
|
| 2000 |
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology. 2: 737-44. PMID 11025665 DOI: 10.1038/35036374 |
0.35 |
|
| 2000 |
Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. The Journal of Clinical Investigation. 105: 1045-7. PMID 10772648 DOI: 10.1172/Jci9872 |
0.53 |
|
| 2000 |
Bergers G, Coussens LM. Extrinsic regulators of epithelial tumor progression: metalloproteinases. Current Opinion in Genetics & Development. 10: 120-7. PMID 10679388 DOI: 10.1016/S0959-437X(99)00043-X |
0.405 |
|
| 1999 |
Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes & Development. 13: 1382-97. PMID 10364156 DOI: 10.1101/Gad.13.11.1382 |
0.449 |
|
| 1999 |
Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (New York, N.Y.). 284: 808-12. PMID 10221914 DOI: 10.1126/Science.284.5415.808 |
0.49 |
|
| 1998 |
Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 93: 411-22. PMID 9590175 DOI: 10.1016/S0092-8674(00)81169-1 |
0.358 |
|
| 1998 |
Bergers G, Hanahan D, Coussens LM. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. The International Journal of Developmental Biology. 42: 995-1002. DOI: 10.1387/Ijdb.9853830 |
0.471 |
|
| Show low-probability matches. |